Market Intelligence
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Ivabradine Prices Rise High Among Recent UK Launches In April
Ivabradine stood out among recently-launched UK generics with an average price rise of more than a third in April, according to the latest figures from market researcher WaveData.

Samsung Bioepis Biosimilars Report Sees Lower Price Boosting Uptake
Samsung Bioepis has published the first in a planned series of reports on the US biosimilars market, including insights into pricing, uptake and market share for various biosimilars.

Perindopril And Pramipexole Prices Peak In March
Two products featured highly among the fastest-rising UK generics prices in March, but for different reasons.

The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.

‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars
With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – tells Generics Bulletin that the US biosimilars market is ‘doing better, but we still have improvements to make.’

Wholesaler Hike Drives UK Price Spike In February
Increases by one particular wholesaler led to steep rises for a number of UK generics in February, according to market researcher WaveData.

Organon: Adalimumab Sales Won’t Surpass $100m In 2023, Despite US Launch
Organon has provided a relatively clear guide for how its planned launch of a US biosimilar to AbbVie’s Humira in July will impact its top line in 2023, with further detail on the coming years.

New Pricing Policies Needed To Curb AMR Impact, States Industry Alliance Report
The AMR Industry Alliance has put forward six different policy proposals which it says could minimize the global impact of antimicrobial resistance.

Orion Bemoans Bad Luck In Winner-Takes-All Biosimilar Tenders
Finland’s Orion is continuing to await the potentially uplifting effect of its biosimilar partnership with Aurobindo’s CuraTeQ Biologics, after another tricky year.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.